GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project

2014 ◽  
Vol 41 (6) ◽  
pp. 1244-1248 ◽  
Author(s):  
Oliver FitzGerald ◽  
Philip J. Mease ◽  
Philip S. Helliwell ◽  
Vinod Chandran
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Joint Damage ◽  
Classification Criteria ◽  
Undifferentiated Arthritis ◽  
Psoriatic Disease ◽  
Inflammatory Bowel ◽  
Peripheral Spondyloarthritis ◽  
Arthritis Mutilans ◽  
Made In

At the 2013 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), several key GRAPPA projects on musculoskeletal aspects of psoriatic disease were reviewed. In this article, lead investigators summarize the progress made in a multicenter study, the PsA BioDam (Psoriatic Arthritis Biomarkers for Joint Damage), to identify soluble biomarkers for joint damage, as well as developing classification criteria for arthritis mutilans. Also reviewed are concepts and rationale behind a proposal to study classification criteria for peripheral spondyloarthritis, including PsA, reactive arthritis, inflammatory bowel disease-associated arthritis, and undifferentiated arthritis.

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting

2021 ◽  
pp. jrheum.201671
Author(s):  
Philip J. Mease ◽  
Leonard H. Calabrese ◽  
Kristina Callis Duffin ◽  
Rebecca H. Haberman ◽  
Rodrigo Firmino ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Severe Disease ◽  
Vaccine Safety ◽  
Global Scale ◽  
Disease Course ◽  
Risk Of Infection ◽  
Psoriatic Disease ◽  
Increased Risk ◽  
Infectious Disease Specialists

The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.

Strategies for Biomarker Development in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 423-426 ◽  
Author(s):  
CHRISTOPHER T. RITCHLIN
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Psoriatic Arthritis ◽  
Psoriatic Disease ◽  
Funding Sources ◽  
Inflammatory Bowel ◽  
Biomarker Research ◽  
Anxiety Depression ◽  
Collaborative Efforts ◽  
Musculoskeletal Involvement

Psoriatic disease includes psoriasis and associated comorbidities (arthritis, uveitis, inflammatory bowel disease, cardiovascular disease, metabolic syndrome, and anxiety/depression) and is remarkably diverse in disease presentation and course. The marked heterogeneity of musculoskeletal involvement in psoriatic arthritis (PsA) presents major challenges to clinicians regarding diagnosis, risk stratification, and management. Members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have begun collaborative efforts to develop biomarkers that can assist in the diagnosis and management of patients with psoriasis and related comorbidities. This brief review provides a rationale for biomarker research in PsA, consideration of types and sources of biomarkers, and examples of important biomarker studies in PsA, followed by a review of trial designs for biomarker research and a discussion of potential funding sources.

Arthritis Mutilans: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1419-1422 ◽  
Author(s):  
Vinod Chandran ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell ◽  
Björn Gudbjörnsson
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Clinical Features ◽  
Severe Form ◽  
Group Discussions ◽  
Epidemiological Research ◽  
Breakout Group ◽  
Definition Of ◽  
Arthritis Mutilans ◽  
Broad Consensus

Arthritis mutilans is often described as the most severe form of psoriatic arthritis. However, a widely agreed on definition of the disease has not been developed. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members hoped to agree on a definition of arthritis mutilans and thus facilitate clinical and molecular epidemiological research into the disease. Members discussed the clinical features of arthritis mutilans and definitions used by researchers to date; reviewed data from the ClASsification for Psoriatic ARthritis study, the Nordic psoriatic arthritis mutilans study, and the results of a premeeting survey; and participated in breakout group discussions. Through this exercise, GRAPPA members developed a broad consensus on the features of arthritis mutilans, which will help us develop a GRAPPA-endorsed definition of arthritis mutilans.

scholarly journals GRAPPA Trainees Symposium 2013: A Report from the GRAPPA 2013 Annual Meeting

2014 ◽  
Vol 41 (6) ◽  
pp. 1200-1205 ◽  
Author(s):  
Agnes Szentpetery ◽  
Mary Ann N. Johnson ◽  
Christopher T. Ritchlin
Keyword(s):  
Psoriatic Arthritis ◽  
Clinical Research ◽  
Annual Meeting ◽  
Psoriatic Disease ◽  
The World ◽  
Oral Presentations

At the 2013 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Toronto, Ontario, Canada, 26 dermatology and rheumatology fellows engaged in psoriasis or psoriatic arthritis research were invited to present their work at the Trainees Symposium, which preceded the annual meeting and was also attended by GRAPPA members from around the world. Herein, we provide a brief overview of the 6 oral presentations and 25 posters presented, which reflect the focus and diversity of current basic and clinical research in psoriatic disease.

GRAPPA Trainees Symposium 2010: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 394-397 ◽  
Author(s):  
CHRISTOPHER T. RITCHLIN
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Psoriatic Disease ◽  
Oral Presentations

At the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), 24 trainees (rheumatology fellows and dermatology residents) engaged in research in psoriatic disease were invited to present their work at the Trainees Symposium, which preceded the GRAPPA meeting and was also attended by GRAPPA members and invited guests. Nineteen posters and 6 oral presentations were presented by the trainees, all of which are summarized here.

scholarly journals Early Diagnosing and Treatment of Rheumatoid Arthritis, Benefits of Anti-Citrullinated Peptides Examination

2017 ◽  
Vol 17 (2) ◽  
pp. 28-31
Author(s):  
Gabriela Belakova ◽  
V. Manka ◽  
E. Zanova ◽  
P. Racay
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Damage ◽  
Classification Criteria ◽  
Disease Course ◽  
Undifferentiated Arthritis ◽  
Disease Pathogenesis ◽  
Erosive Disease ◽  
Correlate Data

AbstractBackground: Anti-citrullinated peptides antibodies (ACPA) are specific for rheumatoid arthritis and have been implicated in disease pathogenesis. ACPA examination is a new component of ACR/EULAR 2010 classification criteria for rheumatoid arthritis. ACPA positivity predicts a more erosive disease course with severe joint damage and extra-articular manifestations. Objectives: To evaluate the benefits of ACPA examination in patients with early undifferentiated arthritis and patients with rheumatoid arthritis. Methods: We examined patients with arthritis and tested them for ACPA positivity. In every individual patient we evaluated if ACPA examination was necessary to establish the diagnosis of rheumatoid arthritis, or to change treatment, or if the diagnosis could have been established without ACPA examination (ACR/EULAR 2010 classification criteria was met without ACPA scoring). Results and Conclusions: We examined 833 patients with arthritis. There were 43 patients, or 62 % of a subgroup of 69 who were ACPA positive whose ACPA examination was not needed - ACR/EULAR criteria was met without ACPA scoring. This number represents 5.1 % of the total number examined. There were 15 patients, or 22 % of the subgroup and 1.8 % of the total whose diagnosis was revised to rheumatoid arthritis due to ACPA positivity - ACR/EULAR criteria was met solely with ACPA scoring. There were 11 patients (16 % and 1.3 %) whose medication was changed due to ACPA positivity. ACPA examination is useful in 3,1 % of all examined patients. When we correlate data on ACPA positive patients, 38 % of the patients profit from ACPA examinations. Considering the relatively low price of ACPA testing, this examination should not be excluded.

Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1428-1433 ◽  
Author(s):  
Alice B. Gottlieb ◽  
April W. Armstrong
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Outcome Measures ◽  
Self Esteem ◽  
The Other ◽  
Atherosclerotic Cardiovascular Disease ◽  
Multisystem Disease ◽  
Psoriatic Disease ◽  
Musculoskeletal Manifestations ◽  
Excess Alcohol Consumption

Psoriasis is a multisystem disease. The cutaneous and musculoskeletal manifestations (psoriatic arthritis) are well recognized. However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members addressed the need to develop uniform, validated, standardized outcome measures for psoriatic disease, measures that are useful to all stakeholders including patients, physicians, regulators, and payers.

Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2014 GRAPPA Annual Meeting

2015 ◽  
Vol 42 (6) ◽  
pp. 1056-1058 ◽  
Author(s):  
Kristina Callis Duffin ◽  
Philip J. Mease
Keyword(s):  
Medical Education ◽  
Psoriatic Arthritis ◽  
Continuing Education ◽  
Annual Meeting ◽  
Proficiency Testing ◽  
Continuing Medical Education ◽  
Global Education ◽  
Education Programs ◽  
Psoriatic Disease ◽  
Online Videos

At the 2014 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members were updated on Internet-based and continuing education programs in psoriasis and psoriatic arthritis (PsA). The psoriasis and PsA GRAPPA video project, started in 2010, now comprises a set of 15 online videos that provide standardized psoriatic disease endpoint training and proficiency testing for clinicians and researchers. The GRAPPA Global Education Project, started in 2012, comprises several continuing medical education (CME) and non-CME initiatives to educate dermatologists, rheumatologists, and trainees about PsA and psoriasis.

Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary

2020 ◽  
Vol 5 (2) ◽  
pp. 68-72
Author(s):  
Rebecca Haberman ◽  
Lourdes M. Perez-Chada ◽  
Evan Siegel ◽  
Anthony M. Reginato ◽  
Dan Webster ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
York City ◽  
Clinical Care ◽  
Delphi Survey ◽  
Psoriatic Disease ◽  
Areas Of Interest ◽  
Ongoing Project

The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) was established to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration, education, and innovative research. This article is a report of the 2018 PPACMAN Annual Meeting held in New York City, on December 8, 2018. At this meeting, attendees discussed the benefits and challenges of combined dermatology/rheumatology clinics and PPACMAN ongoing project updates. In addition, collaborators participated in breakout sessions and plenary voting dedicated to achieving consensus on terminology for preclinical psoriatic arthritis studies, one of PPACMAN’s main areas of interest. The data obtained from this voting exercise were used to draft a formal Delphi survey that is currently underway.

Sign in / Sign up

Export Citation Format

Share Document